abstract |
The present invention relates to novel uses of anti-CD40 antibodies in the treatment of diseases or conditions associated with neoplastic B-cell growth in human patients, in particular anti-CD40 antibodies in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). It relates to the use of. The invention is particularly useful for the treatment of patients who have previously been administered (i) CHOP, (ii) chimeric anti-CD20 monoclonal antibody rituximab, or (iii) a combination therapy of CHOP and rituximab. |